Edgar Filing: HAEMONETICS CORP - Form 8-K

HAEMONETICS CORP Form 8-K August 02, 2010

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 29, 2010
HAEMONETICS CORPORATION

(Exact name of registrant as specified in its charter)

Massachusetts1-1404104-2882273(State or other jurisdiction of incorporation)(Commission (I.R.S. Employer Identification No.)

400 Wood Road

02184

(Address of principal executive offices)

(Zip Code)

Registrant s telephone number, including area code 781-848-7100

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: HAEMONETICS CORP - Form 8-K

Item 5.02(b) Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

On July 29, 2010, Brad Nutter, Executive Chairman of the Board, announced his plan to retire from his position on November 1, 2010. Mr. Nutter s retirement marks the end of the CEO succession plan that began with the announcement in October, 2008 that Brian Concannon, then Chief Operating Officer, would replace Brad Nutter as President and CEO and Brad Nutter would assume the role of Executive Chairman of the Board. Brian Concannon was appointed President and CEO as of April 1, 2009.

Item 9.01 FINANCIAL STATEMENTS AND EXHIBITS

(c) Exhibits

99.1: Press Release of Haemonetics Corporation dated August 2, 2010 announcing the retirement of Brad Nutter.

Edgar Filing: HAEMONETICS CORP - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HAEMONETICS CORPORATION

(Registrant)

Date: August 2, 2010 /s/ Christopher Lindop

Christopher Lindop, Chief Financial

Officer

and VP Business Development

3